ArticleThe Journal of allergy and clinical immunology2012
Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients.
Article in The Journal of allergy and clinical immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 232 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Mild Asthma
Utility of Biomarkers in Evaluating Responsiveness to Anti-IgE (Omalizumab) in Severe Asthma Patients
Who cites it
232 citing papers in PubMed, 3 syntheses or guidelines pooled it, 606 citations in OpenAlex.
- Defining the Role and Clinical Relevance of Periostin in Chronic Rhinosinusitis with or without Nasal Polyps: a Systematic Review and Meta-analysis.Current allergy and asthma reports · 2026Pooled it
- Periostin in allergic rhinitis: from pathogenic mediator to predictive biomarker and therapeutic target.Frontiers in pharmacology · 2026Pooled it
- A meta-analysis of anti-interleukin-13 monoclonal antibodies for uncontrolled asthma.PloS one · 2019Pooled it
- Trial
- Effect of atorvastatin on serum periostin and blood eosinophils in asthma - a placebo-controlled randomized clinical trial.The Journal of international medical research · 2021Trial
- A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2020Trial
- Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial.Respiratory research · 2018Trial
- Obesity's effect on asthma extends to diagnostic criteria.The Journal of allergy and clinical immunology · 2018Trial
- Exploration of the Sphingolipid Metabolite, Sphingosine-1-phosphate and Sphingosine, as Novel Biomarkers for Aspirin-exacerbated Respiratory Disease.Scientific reports · 2016Trial
- Serum periostin is associated with type 2 immunity in severe asthma.The Journal of allergy and clinical immunology · 2016Trial
- Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: Potential benefits of calcitriol.The Journal of allergy and clinical immunology · 2015Trial
- Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.Thorax · 2015Trial
- Bridging environmental pollution and immune dysregulation: How microplastics disrupt gut homeostasis to promote allergic diseases.Virulence · 2026Review
- Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease.Clinical and translational allergy · 2026Review
- Different Inflammatory Phenotypes and Immune Endotypes Drive Disease Heterogeneity in Asthma and COPD.Clinical reviews in allergy & immunology · 2026Review
- Restoring the Airway Barrier: How Targeting Eosinophilic Inflammation Shapes Epithelial Health and Clinical Remission in Asthma.Diagnostics (Basel, Switzerland) · 2026Review
- Circulating Interleukin-11 Across Allergic and Non-Allergic Airway Disease Phenotypes: A Single-Center Exploratory Study.Life (Basel, Switzerland) · 2026Article
- The Effect on Vitamin D Levels and VDR Gene Polymorphism on Clinical Outcomes in Asthma.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026Article
- Integrated molecular networks reveal latent components distinguishing type 2-high and type 2-low asthma.BMJ open respiratory research · 2026Article
- Using cell-specific late-phase asthma mRNA biomarkers to repurpose drugs that concurrently reverse disease signatures across multiple immune cell-types.PLoS computational biology · 2026Article
172 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 3 countries.
Funding
Abstract
backgroundEosinophilic airway inflammation is heterogeneous in asthmatic patients. We recently described a distinct subtype of asthma defined by the expression of genes inducible by T(H)2 cytokines in bronchial epithelium. This gene signature, which includes periostin, is present in approximately half of asthmatic patients and correlates with eosinophilic airway inflammation. However, identification of this subtype depends on invasive airway sampling, and hence noninvasive biomarkers of this phenotype are desirable.
objectiveWe sought to identify systemic biomarkers of eosinophilic airway inflammation in asthmatic patients.
methodsWe measured fraction of exhaled nitric oxide (Feno), peripheral blood eosinophil, periostin, YKL-40, and IgE levels and compared these biomarkers with airway eosinophilia in asthmatic patients.
resultsWe collected sputum, performed bronchoscopy, and matched peripheral blood samples from 67 asthmatic patients who remained symptomatic despite maximal inhaled corticosteroid treatment (mean FEV(1), 60% of predicted value; mean Asthma Control Questionnaire [ACQ] score, 2.7). Serum periostin levels are significantly increased in asthmatic patients with evidence of eosinophilic airway inflammation relative to those with minimal eosinophilic airway inflammation. A logistic regression model, including sex, age, body mass index, IgE levels, blood eosinophil numbers, Feno levels, and serum periostin levels, in 59 patients with severe asthma showed that, of these indices, the serum periostin level was the single best predictor of airway eosinophilia (P = .007).
conclusionPeriostin is a systemic biomarker of airway eosinophilia in asthmatic patients and has potential utility in patient selection for emerging asthma therapeutics targeting T(H)2 inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.